Merck & Co., Inc.MRK

NYSEHealthcarePharmaceuticals$115.62-0.25%

A global pharmaceutical company focused on prescription medicines, vaccines, and biologic therapies, Merck generates a significant share of revenue from its oncology franchise, led by blockbuster immunotherapy Keytruda. The company also maintains a sizable vaccines business and an expanding pipeline in oncology, infectious diseases, and cardiometabolic conditions. Investors monitor patent expiration timelines, clinical trial outcomes, and capital allocation as key drivers of long-term earnings growth.

Market Cap: $285.9B52W Range: $73.31 – $125.14

Congressional Interest in Merck & Co., Inc. (MRK)

9 members of Congress have disclosed 17 trades in Merck & Co., Inc. (MRK), a Healthcare company. The buy/sell breakdown shows 6 purchases versus 11 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.